Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) just unveiled an announcement.
Qiagen has disclosed a voting rights announcement following notification from the Dutch financial markets regulator AFM that DWS Investment GmbH holds a significant stake in the company. As of a transaction dated January 23, 2026, DWS holds approximately 1.69% of Qiagen’s share capital and 2.98% of its voting rights indirectly through ordinary shares, signaling a notable institutional investor position in the stock and potentially influencing shareholder dynamics and governance matters.
The most recent analyst rating on (QGEN) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V., based in Venlo, Netherlands, is a life sciences and molecular diagnostics company whose shares trade on multiple European exchanges as well as the NYSE and Swiss markets. The company’s stock is registered under ISIN NL0015002SN0 and is subject to oversight and disclosure requirements in the jurisdictions where it is listed.
Average Trading Volume: 1,827,255
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.17B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.